• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    4 Penny Stocks Insiders Are Buying

    1/7/22 6:52:14 AM ET
    $AAIC
    $CLRO
    $INM
    $OSAT
    Real Estate Investment Trusts
    Real Estate
    Telecommunications Equipment
    Utilities
    Get the next $AAIC alert in real time by email

    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    InMed Pharmaceuticals

    • The Trade: InMed Pharmaceuticals Inc. (NASDAQ:INM) SVP Aaron Shane Johnson acquired a total of 8500 shares at an average price of $1.26. To acquire these shares, it cost $10,710.00.
    • What’s Happening: InMed Pharmaceuticals recently announced publication of article on CBN as possible glaucoma treatment.
    • What InMed Pharmaceuticals Does: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids.

    Orbsat

    • The Trade: Orbsat Corp. (NASDAQ:OSAT) Vice Chairman And Chief Business Development Strategist Douglas Ellenoff acquired a total of 46297 shares at an average price of $3.24. The insider spent $150,002.28 to buy those shares.
    • What’s Happening: Orbsat recently reported a $7.2 million private placement.
    • What Orbsat Does: Orbsat Corp provides satellite-based asset tracking and monitoring services which also includes ground station construction, product design, and engineering services.

    Arlington Asset Investment

    • The Trade: Arlington Asset Investment Corp. (NYSE:AAIC) President and CEO Rock Tonkel Jr acquired a total of 65866 shares at an average price of $3.61. To acquire these shares, it cost $36,070.00.
    • What’s Happening: Arlington Asset Investment, last month, declares Q4 dividends on preferred stock.
    • What Arlington Asset Investment Does: Arlington Asset Investment Corp is a U.S. based principal investment company. The company holds a leveraged MBS investment portfolio, including Agency MBS, private-label MBS, private-label interest-only MBS, and net long TBA positions, with Agency MBS accounting for the majority of total investment capital.

    ClearOne

    • The Trade: ClearOne, Inc. (NASDAQ:CLRO) 10% owner Edward D Bagley acquired a total of 1538461 shares at an average price of $1.30. The insider spent $1,999,999.30 to buy those shares.
    • What’s Happening: ClearOne highlighted introduction of DIALOG 10 USB single-channel wireless USB mic.
    • What ClearOne Does: ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication.
    Get the next $AAIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAIC
    $CLRO
    $INM
    $OSAT

    CompanyDatePrice TargetRatingAnalyst
    InMed Pharmaceuticals Inc.
    $INM
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AAIC
    $CLRO
    $INM
    $OSAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bagley Edward D bought $1,000,000 worth of shares (2,000,000 units at $0.50), increasing direct ownership by 19% to 12,590,528 units (SEC Form 4)

    4 - CLEARONE INC (0000840715) (Issuer)

    2/28/25 4:05:40 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/22/24 1:38:46 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/21/24 2:58:17 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAIC
    $CLRO
    $INM
    $OSAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Boehnke Eric

    3 - CLEARONE INC (0000840715) (Issuer)

    12/30/25 6:21:53 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    SEC Form 4 filed by Sr VP & General Manager Johnson Shane Aaron

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:54 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    12/19/25 11:42:35 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAIC
    $CLRO
    $INM
    $OSAT
    SEC Filings

    View All

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 8:51:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by InMed Pharmaceuticals Inc.

    10-Q - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    2/11/26 5:04:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ClearOne Inc. (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - CLEARONE INC (0000840715) (Filer)

    2/3/26 1:49:20 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    $AAIC
    $CLRO
    $INM
    $OSAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for December 11th

    NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please Schedule 1x1 Meetings Here "We are excited to host our Life Sciences Virtual Investor Forum on December 11th," said Jason Paltrowitz,

    12/9/25 8:35:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ClearOne Announces Closure of Asset Sale Transaction

    ClearOne, Inc. (NASDAQ:CLRO), a technology innovator and global competitor in the conferencing, collaboration, and network streaming solutions market, today announced that it has entered into a definitive agreement to sell certain assets to Biamp Systems, LLC, a leading global provider of professional audio-visual solutions. This asset sale is part of ClearOne's ongoing strategic process and in support of its previously disclosed plan to pursue one or more transactions involving eventual sale of all or substantially all of the Company's current assets and operations. Under the terms of the agreement, Biamp will acquire intellectual property, product inventory, and customer data among othe

    10/27/25 9:30:00 AM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $AAIC
    $CLRO
    $INM
    $OSAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    11/29/21 6:20:24 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JonesTrading reiterated coverage on Arlington Asset Inv with a new price target

    JonesTrading reiterated coverage of Arlington Asset Inv with a rating of Buy and set a new price target of $5.00 from $4.00 previously

    5/10/21 9:22:12 AM ET
    $AAIC
    Real Estate Investment Trusts
    Real Estate

    Roth Capital reiterated coverage on InMed Pharmaceuticals with a new price target

    Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously

    2/16/21 11:09:34 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAIC
    $CLRO
    $INM
    $OSAT
    Leadership Updates

    Live Leadership Updates

    View All

    InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

    VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid

    12/12/22 6:47:35 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Announces Changes to its Board of Directors

    VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets.  Throughout her career, Ms. Lemerond has worked with public

    8/9/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Announces Appointment of Chief Operating Officer

    VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa

    7/18/22 7:30:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAIC
    $CLRO
    $INM
    $OSAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

    SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/12/24 1:44:16 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ClearOne Inc. (DE) (Amendment)

    SC 13D/A - CLEARONE INC (0000840715) (Subject)

    3/18/24 4:45:12 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    $AAIC
    $CLRO
    $INM
    $OSAT
    Financials

    Live finance-specific insights

    View All

    ClearOne, Inc. Clarifies Dividend Date for Special Stock Dividend

    On June 30, 2025, ClearOne (NASDAQ:CLRO) announced that its Board of Directors had declared a one-time special stock dividend on the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), and any Common Stock equivalents with dividend rights (the "Common Stock Equivalents"), to provide its legacy stockholders with a 100% stake in the proceeds from an eventual sale, if any, of all or substantially all of the Company's current assets and operations in one or more transactions (collectively, the "Asset Sale"). The Board of Directors fixed July 11, 2025 as the record date (the "Record Date") for the Special Stock Dividend, and the Special Stock

    7/10/25 7:00:00 AM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    ClearOne, Inc. Announces a Special One-time Stock Dividend

    ClearOne (NASDAQ:CLRO) today announced that its Board of Directors has declared a one-time special stock dividend on the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), and any Common Stock equivalents with dividend rights (the "Common Stock Equivalents"), to provide its legacy stockholders with a 100% stake in the proceeds from any eventual sale of all or substantially all of the Company's current assets and operations in one or more transactions (collectively, the "Asset Sale"). This Special Stock Dividend is part of the Company's ongoing strategic process and in support of its previously disclosed plan to pursue one or more tran

    6/30/25 4:30:00 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    - Full Year 2024 Operating Expenses decreased 9.8% vs prior year - - Q4 Revenue and Q4 Gross Margin increased 18.1% and 44.8%, respectively, vs. prior quarter - ClearOne (NASDAQ:CLRO), a global provider of audio and visual communication solutions, reported financial results for the three- and twelve-month periods ended December 31, 2024. "Throughout the fourth quarter, we maintained efforts to expand and accelerate shipments of our award-winning communication solutions, all while driving a leaner, more efficient cost structure," said Derek Graham, CEO of ClearOne. "We delivered strong momentum in the fourth quarter of 2024 with revenue increasing 18.1% sequentially compared to Q3 2024. G

    3/31/25 4:06:00 PM ET
    $CLRO
    Telecommunications Equipment
    Utilities